Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

NCT02247037 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT02247037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02247037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Observational
Overall status
Completed
Start date
July 31, 2014
Completion date
January 22, 2019
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer